Loading…
Reported covered position: Congressional Staff, Rep. Greenwood, 2001-2004
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CELGENE CORPORATION via CELGENE CORPORATION
2016 · fourth_quarter · Q4
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
Source: Senate LDA
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Patients' Access to Treatments Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Cancer Drug Coverage Parity Act of 2015
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
-H.R. 3673
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
coding related to wound care products; proposed changes to REMS (H.R. 5657)
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
H.R. 3091,"MODDERN Cures Act of 2013", all provisions.
H.R. 3757,"Igniting American Research Act",all provisions.
SGR Repeal and Medicare Beneficiary Access Act of 2013
Client: CELGENE CORPORATION · Firm: CELGENE CORPORATION
S.1871,"SGR Repeal and Medicare Beneficiary Access Act of 2013", all provisions.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · second_quarter · 2A
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · third_quarter · 3A
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · third_quarter · Q3
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · second_quarter · Q2
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Corporate Tax Reform.
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2016 · first_quarter · Q1
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
Corporate Tax Reform.
CELGENE CORPORATION via CELGENE CORPORATION
2015 · second_quarter · 2A
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · fourth_quarter · Q4
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
Corporate Tax Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · third_quarter · 3A
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Corporate Tax Reform.
CELGENE CORPORATION via CELGENE CORPORATION
2015 · second_quarter · Q2
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
HR 2841, "FAST Generic Act of 2015", regarding all provisions. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. HR 6, "21st Century Cures", regarding all provisions. Issues related to Medicare Part D/Part B. Issues related to the Afforable Care Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via CELGENE CORPORATION
2015 · first_quarter · Q1
patent issues in China; patent issues in Canada; issues related to the Patent Trial and Appeal Board; implementation of patent linkage mechanisms; H.R.9 (Innovation Act); S. 632 (STRONG Patents Act)
H.R. 1600 (Patient Access to Treaments Act); oral parity; exclusivity incentives for dormant therapies; proposed changes to FDA-authorized risk evaluation and mitigation strategies
general issues related to patient access
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · fourth_quarter · Q4
issues surrounding oral parity and specialty tiers (H.R. 460 and H.R. 1801); issues surrounding potential new incentives for research into unmet medical needs (H.R. 3116)
coding related to wound care products; proposed changes to REMS (H.R. 5657)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · third_quarter · Q3
REMS proposals, including Stivers-Welch (H.R. 5657); MODDERN Cures Act (H.R. 3116); oral parity (H.R. 1801); specialty tier/cost sharing (H.R. 460); proposed orphan drug policies; other issues related to dormant therapies, including proposed legislation to expand incentives
coding related to wound care products
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2014 · second_quarter · Q2
implementation of the Affordable Care Act; specialty tier legislation; cost sharing with respect to pharmaceuticals; oral oncology parity
CMS policies related to biomaterials
issues related to patent reform; USPTO practices and procedure; 21st Century Cures Initiative; orphan drug policies
CELGENE CORPORATION via CELGENE CORPORATION
2014 · first_quarter · Q1
-H.R. 3673
-oral oncology parity (H.R. 1801) -340(b) organization and ongoing implementation -Medicare Parts B&D -implementation of Affordable Care Act-speciality tiers related to pharmaceuticals -H.R. 3091 (MODDERN Cures Act)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
CELGENE CORPORATION via CELGENE CORPORATION
2013 · fourth_quarter · Q4
H.R. 3091,"MODDERN Cures Act of 2013", all provisions.
H.R. 3757,"Igniting American Research Act",all provisions.
S.1871,"SGR Repeal and Medicare Beneficiary Access Act of 2013", all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
implementation of Affordable Care Act
implementation of the Affordable Care Act
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)